Aviance Capital Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.19M Buy
2,378
+254
+12% +$258K 0.26% 87
2025
Q4
$2.28M Sell
2,124
-106
-5% -$101K 0.26% 85
2025
Q3
$1.7M Sell
2,230
-215
-9% -$160K 0.2% 103
2025
Q2
$1.91M Sell
2,445
-16
-0.7% -$12.4K 0.25% 95
2025
Q1
$2.03M Sell
2,461
-36
-1% -$30K 0.29% 81
2024
Q4
$1.93M Sell
2,497
-4,422
-64% -$3.66M 0.27% 89
2024
Q3
$6.13M Buy
6,919
+2,675
+63% +$2.4M 0.81% 28
2024
Q2
$3.84M Sell
4,244
-1,431
-25% -$1.14M 0.55% 46
2024
Q1
$4.42M Buy
5,675
+4,115
+264% +$2.93M 0.66% 40
2023
Q4
$909K Hold
1,560
0.19% 126
2023
Q3
$838K Buy
1,560
+338
+28% +$174K 0.19% 131
2023
Q2
$573K Buy
1,222
+176
+17% +$73.8K 0.12% 171
2023
Q1
$359K Sell
1,046
-1
-0.1% -$337 0.08% 198
2022
Q4
$383K Buy
1,047
+263
+34% +$93.2K 0.09% 198
2022
Q3
$254K Sell
784
-1
-0.1% -$317 0.06% 224
2022
Q2
$254K Buy
785
+1
+0.1% +$300 0.06% 233
2022
Q1
$225K Buy
+784
New +$202K 0.04% 242
2014
Q1
Sell
-11,314
Closed -$577K 225
2013
Q4
$577K Buy
11,314
+6,523
+136% +$327K 0.24% 124
2013
Q3
$241K Sell
4,791
-99
-2% -$5.18K 0.11% 187
2013
Q2
$240K Buy
+4,890
New +$266K 0.13% 170

Other funds holding LLY

Aviance Capital Partners's LLY Position: Q1 2026 in Review

Aviance Capital Partners increased its Eli Lilly (LLY) stake by 12% in Q1 2026, buying an estimated $258K and bringing the position to 2,378 shares worth $2.19M. The position accounts for 0.26% of the portfolio, ranked #87.

Aviance Capital Partners first reported a position in LLY in Q2 2013 and has held it in 20 quarters since. The position peaked at $6.13M in Q3 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Aviance Capital Partners held 2,378 shares of Eli Lilly worth $2.19M as of Q1 2026.
  • Aviance Capital Partners bought 254 Eli Lilly shares in Q1 2026, an estimated $258K.
  • Eli Lilly made up 0.26% of Aviance Capital Partners's portfolio in Q1 2026, its #87 holding.
  • Aviance Capital Partners first reported a position in Eli Lilly in Q2 2013 and has held it in 20 quarters since.
  • Aviance Capital Partners's Eli Lilly position peaked at $6.13M in Q3 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Aviance Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.